Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01009866 : Study of Immunotoxin, MR1-1
PhasePhase 1
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Residual, progressive, or recurrent supratentorial malignant brain tumor based on
imaging studies with measurable disease (>0.5cm).

- Patient will have completed some form of radiation therapy prior to toxin treatment.

- Karnofsky Performance score >70.

- The presence of the target antigen, EGFRvIII, must be identified on tumor tissue by

- Platelet count > 100 x 109/L; PTT and PT < 120% of normal range.

- Creatinine < 120% of normal range.

- Total bilirubin, SGOT, SGPT,alkaline phosphatase < 300% of normal range.

Exclusion Criteria:

- Patients who are pregnant, breast-feeding, or unwilling to practice an effective
method of birth control.

- Patients with known potentially anaphylactic allergic reactions to iodine or

- Patients who cannot undergo MRI due to obesity or to having certain metal in their
bodies (specifically pacemakers, infusion pumps, metal aneurysm clips, metal
prostheses, joints, rods or plates).

- Patients that have not recovered from the toxic effects of prior chemotherapy and/or
radiation therapy.

- Patients with an impending, life-threatening cerebral herniation syndrome.

- Patients with subependymal or CSF disease.

- Patients who are under the age of 18 years.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557